Ocugen Statistics
Total Valuation
Ocugen has a market cap or net worth of $527.82 million. The enterprise value is $528.22 million.
Important Dates
The next estimated earnings date is Wednesday, March 4, 2026, before market open.
| Earnings Date | Mar 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Ocugen has 312.32 million shares outstanding. The number of shares has increased by 12.36% in one year.
| Current Share Class | 312.32M |
| Shares Outstanding | 312.32M |
| Shares Change (YoY) | +12.36% |
| Shares Change (QoQ) | +4.09% |
| Owned by Insiders (%) | 1.49% |
| Owned by Institutions (%) | 21.44% |
| Float | 307.66M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 92.79 |
| Forward PS | 206.16 |
| PB Ratio | 149.40 |
| P/TBV Ratio | 149.40 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 98.36 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.85, with a Debt / Equity ratio of 9.33.
| Current Ratio | 1.85 |
| Quick Ratio | 1.60 |
| Debt / Equity | 9.33 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -16.16 |
Financial Efficiency
Return on equity (ROE) is -289.93% and return on invested capital (ROIC) is -90.71%.
| Return on Equity (ROE) | -289.93% |
| Return on Assets (ROA) | -63.67% |
| Return on Invested Capital (ROIC) | -90.71% |
| Return on Capital Employed (ROCE) | -163.53% |
| Revenue Per Employee | $56,526 |
| Profits Per Employee | -$673,895 |
| Employee Count | 95 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +131.86% in the last 52 weeks. The beta is 3.50, so Ocugen's price volatility has been higher than the market average.
| Beta (5Y) | 3.50 |
| 52-Week Price Change | +131.86% |
| 50-Day Moving Average | 1.37 |
| 200-Day Moving Average | 1.15 |
| Relative Strength Index (RSI) | 57.97 |
| Average Volume (20 Days) | 5,669,559 |
Short Selling Information
The latest short interest is 46.39 million, so 14.85% of the outstanding shares have been sold short.
| Short Interest | 46.39M |
| Short Previous Month | 58.99M |
| Short % of Shares Out | 14.85% |
| Short % of Float | 15.08% |
| Short Ratio (days to cover) | 12.27 |
Income Statement
In the last 12 months, Ocugen had revenue of $5.37 million and -$64.02 million in losses. Loss per share was -$0.22.
| Revenue | 5.37M |
| Gross Profit | -32.00M |
| Operating Income | -60.89M |
| Pretax Income | -64.02M |
| Net Income | -64.02M |
| EBITDA | -57.51M |
| EBIT | -60.89M |
| Loss Per Share | -$0.22 |
Full Income StatementBalance Sheet
The company has $32.57 million in cash and $32.96 million in debt, with a net cash position of -$399,000 or -$0.00 per share.
| Cash & Cash Equivalents | 32.57M |
| Total Debt | 32.96M |
| Net Cash | -399,000 |
| Net Cash Per Share | -$0.00 |
| Equity (Book Value) | 3.53M |
| Book Value Per Share | 0.01 |
| Working Capital | 17.28M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$53.37 million and capital expenditures -$163,000, giving a free cash flow of -$53.53 million.
| Operating Cash Flow | -53.37M |
| Capital Expenditures | -163,000 |
| Free Cash Flow | -53.53M |
| FCF Per Share | -$0.17 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,133.87% |
| Pretax Margin | -1,192.18% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Ocugen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.36% |
| Shareholder Yield | -12.36% |
| Earnings Yield | -12.13% |
| FCF Yield | -10.14% |
Analyst Forecast
The average price target for Ocugen is $7.00, which is 314.20% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.00 |
| Price Target Difference | 314.20% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 173.82% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ocugen has an Altman Z-Score of -9.61 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.61 |
| Piotroski F-Score | 2 |
